RxDoctor Payments Data

Sasidhar Guthikonda, MD

Interventional Cardiology · Humacao, PRNPI 1851595367

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $463 and has fallen 80.7% since, to $89 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PR, where the typical reported total is $12,032.

$1,517in general payments, 2019–2025

Across 76 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$181
  • Pfizer$128
  • Boehringer Ingelheim$128
  • AstraZeneca$112
  • Amgen$108
  • Inari Medical, Inc.$102
  • plus $758 from 17 others

What the payments were for

  • Food & beverage$1,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,517 in reported general payments places this provider in the 10th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$71,109
Medicare patients
442
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$306,610
EntrestoSacubitril/Valsartan115$120,981
XareltoRivaroxaban53$69,406
Repatha SureclickEvolocumab19$24,657
BrilintaTicagrelor21$18,825
VascepaIcosapent Ethyl14$8,281
FarxigaDapagliflozin Propanediol12$6,753
Prasugrel Hcl55$6,124
ClopidogrelClopidogrel Bisulfate444$4,984
Atorvastatin Calcium568$4,820
Rosuvastatin Calcium385$4,308
Metoprolol Succinate295$4,291
Nifedipine ErNifedipine49$2,619
Flecainide Acetate38$2,461
Metoprolol Tartrate247$1,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$306,610261 claims
NovartisEntresto$181$120,981115 claims
Johnson & JohnsonXarelto$79$69,40653 claims
AstraZenecaBrilinta, Farxiga$112$25,57833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →